June 11, 2011 -- Northeast Pharma of China filed for a $370 million private placement, which will pay for a vitamin C production facility; China Medical System Holdings bought a 51% stake in drugmaker Guangming Pharma, Harbor BioSciences signed an umbrella agreement to distribute generic drugs in the US for a Sinopharm subsidiary; Selected Value Therapeutics will acquire the China rights to an EntreMed cancer drug; the journal Nature published research on the number of China INDs and NDAs since 2003; BGI of Shenzhen set up a genomic research partnership with the University of California, Davis; Agenix announced its schedule for China approval of a new hepatitis B treatment; Foci Pharma is applying for authorization to sell its TCM product in Europe; and Simcere Pharma will receive a $7.7 million settlement from the former owners of its new, and troubled, rabies vaccination facility. More details….
Stock Symbol: (SHA: 000597) (HK: 0867) (OTCBB: HRBR) (NSDQ: ENMD) (ASX: AGX) (NYSE: SCR)
